Liu Xue-Ying, Hanjing Shangguan, Zhang Bing-Huang, Luo Xian-Yang
Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Front Oncol. 2024 Sep 23;14:1430830. doi: 10.3389/fonc.2024.1430830. eCollection 2024.
The objective of this study is to assess the prognostic value of Ki67 and p16 proteins in laryngeal cancer.
This retrospective cohort analysis comprised 260 patients diagnosed with laryngeal cancer. Immunohistochemistry (IHC) was employed to assess the expression levels of p16 and Ki67, and their correlation with the survival time of laryngeal cancer patients was analyzed.
The Ki67 index level exhibited a significant association with the prognosis of laryngeal cancer. Patients with higher Ki67 index levels demonstrated shorter survival times, more severe pathological classification, and higher tumor stages (P < 0.05). Conversely, no significant differences in prognostic characteristics of laryngeal cancer were observed in the p16 (-/+) population ( > 0.05). The median survival times for patients with Ki67 index levels of 0-35%, 36-70%, and 70-100% were 3.54 years, 2.10 years, and 1.92 years, respectively. After adjusting for age, smoking, alcohol consumption, pathological classification, surgical intervention, recurrence, and metastasis, the risk of death for patients with Ki67 index levels of 70-100% was 2.0504 times higher than that of patients with Ki67 index levels of 0-35% (95% CI: 1.2997-3.2345, = 0.0020).
The Ki67 index level is strongly associated with survival time and the risk of death in laryngeal cancer, making it a valuable prognostic indicator. However, the prognostic value of p16 levels in laryngeal cancer is limited. These findings provide important insights for prognosis evaluation and treatment decision-making in patients with laryngeal cancer.
本研究旨在评估Ki67和p16蛋白在喉癌中的预后价值。
本回顾性队列分析纳入了260例诊断为喉癌的患者。采用免疫组织化学(IHC)评估p16和Ki67的表达水平,并分析它们与喉癌患者生存时间的相关性。
Ki67指数水平与喉癌预后显著相关。Ki67指数水平较高的患者生存时间较短,病理分级更严重,肿瘤分期更高(P<0.05)。相反,在p16(-/+)人群中,喉癌的预后特征未观察到显著差异(P>0.05)。Ki67指数水平为0-35%、36-70%和70-100%的患者中位生存时间分别为3.54年、2.10年和1.92年。在调整年龄、吸烟、饮酒、病理分级、手术干预、复发和转移后,Ki67指数水平为70-100%的患者死亡风险比Ki67指数水平为0-35%的患者高2.0504倍(95%CI:1.2997-3.2345,P=0.0020)。
Ki67指数水平与喉癌的生存时间和死亡风险密切相关,使其成为一个有价值的预后指标。然而,p16水平在喉癌中的预后价值有限。这些发现为喉癌患者的预后评估和治疗决策提供了重要的见解。